Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. MarketScreener Strategies
    SAN   FR0000120578

SANOFI

(SAN)
  Report
Real-time Euronext Paris  -  12:39:18 2023-03-24 pm EDT
97.10 EUR   +1.31%
03/24GSK Disagrees With Court Ruling to Allow Plaintiff-Expert Testimony in Goetz Case
DJ
03/24GSK refutes California state court ruling on Zantac's cancer links
AN
03/24SANOFI : Berenberg remains Neutral
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi : Volatility should make a big comeback

03/16/2023 | 02:35am EDT
long trade
Target price hit
Entry price : 89.73€ | Target : 95€ | Stop-loss : 86€ | Potential : 5.87%
An exit from the recently observed accumulation phase to the upside could allow for the assumption that a clear upward trend is re-established with an increase in volatility.
Investors have an opportunity to buy the stock and target the € 95.
Sanofi : Sanofi : Volatility should make a big comeback
Summary
  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

  • Weaknesses
    • Revenue estimates are regularly revised downwards for the current and coming years.
    • For the last few months, analysts have been revising downwards their earnings forecast.

    ę MarketScreener.com 2023

    Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
    The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

    Financials
    Sales 2023 44 459 M 47 826 M 47 826 M
    Net income 2023 8 218 M 8 841 M 8 841 M
    Net Debt 2023 3 158 M 3 398 M 3 398 M
    P/E ratio 2023 14,7x
    Yield 2023 3,81%
    Capitalization 121 B 130 B 130 B
    EV / Sales 2023 2,80x
    EV / Sales 2024 2,52x
    Nbr of Employees 91 573
    Free-Float 88,2%
    Upcoming event on SANOFI
    Income Statement Evolution
    Consensus
    Sell
    Buy
    Mean consensus OUTPERFORM
    Number of Analysts 23
    Last Close Price 97,10 €
    Average target price 106,18 €
    Spread / Average Target 9,35%
    EPS Revisions
    Managers and Directors
    Paul Hudson Chief Executive Officer & Director
    Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
    Serge Weinberg Director
    Nestle Frank Global Head-Immunology Therapeutic Research Area
    Dietmar P. Berger Chief Medical Officer & Global Head-Development
    Sector and Competitors
    1st jan.Capi. (M$)
    SANOFI8.08%130 425
    JOHNSON & JOHNSON-13.59%398 966
    NOVO NORDISK A/S11.83%340 729
    ELI LILLY AND COMPANY-8.12%303 155
    ABBVIE INC.-2.22%278 770
    MERCK & CO., INC.-5.54%266 044
    Stock markets for all
    100% Free Registration
    fermer